Scott Morrison, Director at Global Blood Therapeutics (NASDAQ:GBT), made a large insider sell on September 9, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Morrison sold 4,800 shares of Global Blood Therapeutics at a price of $30.21 per share. The total transaction amounted to $145,003.
Following the transaction, Morrison still owns 3,037 shares of the company, worth $84,914.
Global Blood Therapeutics shares are trading down 0.53% at $27.96 at the time of this writing on Monday morning.
Why Insider Transactions Are Important
Insider transactions shouldn’t be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.
In legal terms, an “insider” refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Important Transaction Codes
Investors prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.